Evidence map›Paper›PMID 25022851›Full record

ArticleJournal of bacteriology2014

Biological cost of pyocin production during the SOS response in Pseudomonas aeruginosa.

Jon Penterman, Pradeep K Singh, Graham C Walker

Open access · bronzeAbstract read
In one paragraph

Article in Journal of bacteriology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
3.7field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 68 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Snapshots ofiScience · 2025
    Article
  7. Genomic analysis of prophages in 44 clinical strains ofFrontiers in cellular and infection microbiology · 2025
    Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. MvaT negatively regulates pyocin S5 expression inBiotechnology notes (Amsterdam, Netherlands) · 2022
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Jon PentermanDepartment of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA pntrmn@mit.edu gwalker@mit.edu.
Pradeep K SinghDepartments of Medicine and Microbiology, University of Washington School of Medicine, Seattle, Washington, USA.
Graham C WalkerDepartment of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA pntrmn@mit.edu gwalker@mit.edu.
Massachusetts Institute of Technology · USUniversity of Washington · US

Funding

VIRUS PRODUCTION COREP30CA014051 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI MATTHEW G. VANDER HEIDEN · 1985 to 2026
$93.9M
TOXICOLOGY CORE UNITP30ES002109 · NIEHS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI YAFFE, MICHAEL B · 1985 to 2020
$25.6M
MOLEULAR GENETICS OF RHIZOBIUM PLASMIDSR01GM031030 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI WALKER, GRAHAM C · 1985 to 2020
$8.6M
MUTAGENESIS AND REPAIR OF DNAR01CA021615 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI WALKER, GRAHAM C · 1985 to 2019
$6.5M
Investigating treatment resistance mechanisms in chronic bacterial infectionsR01AI101307 · NIAID · UNIVERSITY OF WASHINGTON · PI BRUCE, JAMES EDWARD, MANOIL, COLIN · 2012 to 2016
$2.9M
Studies on bacterial populations and therapeutics for CF lung infectionsK24HL102246 · NHLBI · UNIVERSITY OF WASHINGTON · PI SINGH, PRADEEP K · 2010 to 2019
$1.6M
Investigating bacterial-host interactions driving CF Pulmonary ExacerbationsR01HL110879 · NHLBI · UNIVERSITY OF WASHINGTON · PI BRUCE, JAMES EDWARD, SINGH, PRADEEP K · 2011 to 2014
$1.6M
NCI NIH HHS P30 CA014051NCI NIH HHS P30-CA14051NCI NIH HHS R01 CA021615NHLBI NIH HHS K24 HL102246NHLBI NIH HHS K24HL102246NHLBI NIH HHS R01 HL110879NHLBI NIH HHS R01HL110879NIAID NIH HHS R01 AI101307NIAID NIH HHS R01AI101307NIEHS NIH HHS P30 ES002109NIGMS NIH HHS GM31010NIGMS NIH HHS R01 GM031030
6 · The paper itself

Abstract

LexA and two structurally related regulators, PrtR and PA0906, coordinate the Pseudomonas aeruginosa SOS response. RecA-mediated autocleavage of LexA induces the expression of a protective set of genes that increase DNA damage repair and tolerance. In contrast, RecA-mediated autocleavage of PrtR induces antimicrobial pyocin production and a program that lyses cells to release the newly synthesized pyocin. Recently, PrtR-regulated genes were shown to sensitize P. aeruginosa to quinolones, antibiotics that elicit a strong SOS response. Here, we investigated the mechanisms by which PrtR-regulated genes determine antimicrobial resistance and genotoxic stress survival. We found that induction of PrtR-regulated genes lowers resistance to clinically important antibiotics and impairs the survival of bacteria exposed to one of several genotoxic agents. Two distinct mechanisms mediated these effects. Cell lysis genes that are induced following PrtR autocleavage reduced resistance to bactericidal levels of ciprofloxacin, and production of extracellular R2 pyocin was lethal to cells that initially survived UV light treatment. Although typically resistant to R2 pyocin, P. aeruginosa becomes transiently sensitive to R2 pyocin following UV light treatment, likely because of the strong downregulation of lipopolysaccharide synthesis genes that are required for resistance to R2 pyocin. Our results demonstrate that pyocin production during the P. aeruginosa SOS response carries both expected and unexpected costs.

Indexed as

SOS Response, GeneticsAnti-Bacterial AgentsBacterial ProteinsCiprofloxacinDrug Resistance, BacterialGene Expression Regulation, BacterialLexA Repressor ProteinPseudomonas aeruginosaPyocinsSerine EndopeptidasesTranscription FactorsUltraviolet RaysAnti-Bacterial AgentsBacterial ProteinsCiprofloxacinLexA Repressor ProteinPyocinsSerine EndopeptidasesTranscription Factors

Identifiers

PMID25022851
PMCPMC4135695
OpenAlexW2017471456

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.